Skip to main content
Journal cover image

Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies.

Publication ,  Journal Article
Sweeny, L; Prince, A; Patel, N; Moore, LS; Rosenthal, EL; Hughley, BB; Warram, JM
Published in: Laryngoscope
December 2016

OBJECTIVE: Evaluate if vascular normalization with an antiangiogenic monoclonal antibody improves detection of melanoma using fluorescently labeled antibody-based imaging. STUDY DESIGN: Preclinical. METHODS: Panitumumab and control IgG were covalently linked to a near-infrared fluorescent probe (IRDye800CW). Immunodeficient mice with ear xenografts of melanoma cell lines (A375 and SKMEL5) were systemically injected (200 μg, tail vein) with either IgG-IRDye800CW, panitumumab-IRDye800CW, or a combination (bevacizumab [5mg/kg], administered 72 hours prepanitumumab-IRDye800CW) (n = 5). Primary tumors were imaged with open-field (LUNA, Novadaq, Toronto, Ontario, Canada) and closed-field (Pearl, LI-COR Biosciences, Lincoln, NB) imaging devices. Postresection, the concentration of labeled antibody within the tumor (μg/g) was calculated using normalized standards. RESULTS: The mean fluorescence within the melanoma tumors was greater for the combination group compared to panitumumab alone for both cell lines (P < 0.001). The tumor-to-background ratio (TBR) for the A375 tumors was greater for the combination (3.4-7.1) compared to the panitumumab alone (3.2-5.0) (P = 0.04). The TBR for SKMEL5 tumors was greater for the combination (2.4-6.0) compared to the panitumumab alone (2.2-3.9) (P = 0.02). Within A375 tumors, the concentration was lower for panitumumab (0.51 μg/g) compared to combination group (0.68 μg/g) (P = 0.036). Within SKMEL5 tumors, the concentration was lower for panitumumab (0.0.17 μg/g) compared to combination group (0.35 μg/g) (P = 0.048). Residual tumor (1.0-0.2 mg) could be differentiated from background in both panitumumab and combination groups. For both cell lines, panitumumab and combination groups had greater mean fluorescence of the tumor compared to control IgG. CONCLUSION: The addition of antiangiogenic therapy improves uptake of fluorescently labeled monoclonal antibodies within melanoma tumors. Clinical translation could improve detection of melanoma intraoperatively, reducing positive margins and sparing normal tissue. LEVEL OF EVIDENCE: NA Laryngoscope, 126:E387-E395, 2016.

Duke Scholars

Published In

Laryngoscope

DOI

EISSN

1531-4995

Publication Date

December 2016

Volume

126

Issue

12

Start / End Page

E387 / E395

Location

United States

Related Subject Headings

  • Panitumumab
  • Otorhinolaryngology
  • Mice, SCID
  • Mice, Nude
  • Mice
  • Melanoma
  • Indoles
  • Heterografts
  • Fluorescent Dyes
  • Fluorescence
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sweeny, L., Prince, A., Patel, N., Moore, L. S., Rosenthal, E. L., Hughley, B. B., & Warram, J. M. (2016). Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies. Laryngoscope, 126(12), E387–E395. https://doi.org/10.1002/lary.26215
Sweeny, Larissa, Andrew Prince, Neel Patel, Lindsay S. Moore, Eben L. Rosenthal, Brian B. Hughley, and Jason M. Warram. “Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies.Laryngoscope 126, no. 12 (December 2016): E387–95. https://doi.org/10.1002/lary.26215.
Sweeny L, Prince A, Patel N, Moore LS, Rosenthal EL, Hughley BB, et al. Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies. Laryngoscope. 2016 Dec;126(12):E387–95.
Sweeny, Larissa, et al. “Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies.Laryngoscope, vol. 126, no. 12, Dec. 2016, pp. E387–95. Pubmed, doi:10.1002/lary.26215.
Sweeny L, Prince A, Patel N, Moore LS, Rosenthal EL, Hughley BB, Warram JM. Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies. Laryngoscope. 2016 Dec;126(12):E387–E395.
Journal cover image

Published In

Laryngoscope

DOI

EISSN

1531-4995

Publication Date

December 2016

Volume

126

Issue

12

Start / End Page

E387 / E395

Location

United States

Related Subject Headings

  • Panitumumab
  • Otorhinolaryngology
  • Mice, SCID
  • Mice, Nude
  • Mice
  • Melanoma
  • Indoles
  • Heterografts
  • Fluorescent Dyes
  • Fluorescence